financetom
Business
financetom
/
Business
/
Atlassian Insider Sold Shares Worth $1,267,849, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Atlassian Insider Sold Shares Worth $1,267,849, According to a Recent SEC Filing
Aug 27, 2025 3:30 PM

05:58 PM EDT, 08/27/2025 (MT Newswires) -- Michael Cannon-Brookes, 10% Owner, Director, CEO, Co-Founder, on August 26, 2025, sold 7,665 shares in Atlassian ( TEAM ) for $1,267,849. Following the Form 4 filing with the SEC, Cannon-Brookes has control over a total of 183,960 Class A common shares of the company, with 183,960 controlled indirectly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1650372/000156218025006029/xslF345X05/primarydocument.xml

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Dua Lipa beats lawsuit claiming she copied 'Levitating'
Dua Lipa beats lawsuit claiming she copied 'Levitating'
Mar 27, 2025
NEW YORK, March 27 (Reuters) - Dua Lipa won the dismissal on Thursday of a lawsuit in Manhattan accusing the British pop star of copying her 2021 megahit Levitating from a 1979 disco song. U.S. District Judge Katherine Polk Failla said L. Russell Brown and Sandy Linzer failed to show substantial similarity between Levitating and their song Wiggle and Giggle...
Canada's prime minister says nothing off the table in response to Trump's tariffs
Canada's prime minister says nothing off the table in response to Trump's tariffs
Mar 27, 2025
OTTAWA (Reuters) -Canada will wait until next week to respond to the latest U.S. threat of tariffs and nothing is off the table regarding possible countermeasures, Prime Minister Mark Carney said on Thursday. Carney told a press conference that he would speak to provincial premiers and business leaders on Friday to discuss a coordinated response to the auto sector tariffs...
Candel Therapeutics Shares Are Down Today: What's Going On?
Candel Therapeutics Shares Are Down Today: What's Going On?
Mar 27, 2025
Candel Therapeutics, Inc. ( CADL ) shares are are trading lower Thursday after the company released final survival data from its phase 2a clinical trial of CAN-2409. What To Know: The trial involved patients with stage III/IV non-small cell lung cancer (NSCLC) who had inadequate responses to immune checkpoint inhibitor (ICI) treatment. The median overall survival (mOS) was reported at...
Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug
Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug
Mar 27, 2025
The Japanese Ministry of Health, Labour and Welfare on Thursday approved BridgeBio Pharma, Inc. ( BBIO )‘s acoramidis, under the brand name Beyonttra, for adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). Acoramidis is a selective small molecule, orally administered, near-complete (≥90%) transthyretin (TTR) stabilizer. ATTR-CM is a progressive, fatal disease that presents as an infiltrative, restrictive cardiomyopathy, resulting in heart failure. AstraZeneca Plc...
Copyright 2023-2026 - www.financetom.com All Rights Reserved